Doxorubicin (DOX) is the most effective chemotherapeutic drug developed against broad range of cancers such as solid tumours, transplantable leukemias and lymphomas. Conventional DOX-induced cardiotoxicity has limited its use. FDA approved drugs i.e. non-pegylated liposomal (Myocet) and pegylated liposomal (Doxil) formulations have no doubt shown comparatively reduced cardiotoxicity, but has raised new toxicity issues. The entrapment of DOX in biocompatible, biodegradable and safe nano delivery systems can prevent its degradation in circulation minimising its toxicity with increased half-life, enhanced pharmacokinetic profile leading to improved patient compliance. In addition, nano delivery systems can actively and passively target the tumour resulting increase in therapeutic index and decreased side effects of drug. Foreseeing the need of a comprehensive review on DOX nanoformulations, in this article we for the first time have given an updated insight on DOX nano delivery systems.
The present investigation deals with synthesis of new acid dyes from 4-amino-1-(4-sulfophenyl)-3-methyl-5-pyrazolone and phenol derivatives and their metal complexes (Cu (II) and Fe (II)). The phenol derivatives include 4-chlorophenol, 4-nitrophenol, 4-hydroxybenzene sulfonic acid, 2-nitrophenol-4-sulfonic acid, resorcinol and bisphenol A and bisphenol S. The newly synthesized dyes were applied to crust leather to assess their dyeing properties. The fastness properties of unmetallized dyes were less as compared to metal complexes due to the strong interaction of metals with leather protein. The structures of these dyes were also confirmed by UV, FTIR and NMR studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.